CN1507918A - 透皮促进剂甘油三醋酸酯 - Google Patents

透皮促进剂甘油三醋酸酯 Download PDF

Info

Publication number
CN1507918A
CN1507918A CNA2004100392112A CN200410039211A CN1507918A CN 1507918 A CN1507918 A CN 1507918A CN A2004100392112 A CNA2004100392112 A CN A2004100392112A CN 200410039211 A CN200410039211 A CN 200410039211A CN 1507918 A CN1507918 A CN 1507918A
Authority
CN
China
Prior art keywords
matrix patch
triacetin
drug
adhesive
oxybutynin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004100392112A
Other languages
English (en)
Chinese (zh)
Inventor
全丹毅
��ʲ
N·A·德什潘戴
S·温卡特什瓦仁
C·D·埃伯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actavis Laboratories UT Inc
Original Assignee
Theratech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23704623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1507918(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theratech Inc filed Critical Theratech Inc
Publication of CN1507918A publication Critical patent/CN1507918A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2004100392112A 1995-04-26 1996-04-08 透皮促进剂甘油三醋酸酯 Pending CN1507918A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/429,757 US5601839A (en) 1995-04-26 1995-04-26 Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US08/429,757 1995-04-26

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB961934565A Division CN1143688C (zh) 1995-04-26 1996-04-08 透皮促进剂甘油三醋酸酯

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB2005100719966A Division CN100374161C (zh) 1995-04-26 1996-04-08 透皮促进剂甘油三醋酸酯

Publications (1)

Publication Number Publication Date
CN1507918A true CN1507918A (zh) 2004-06-30

Family

ID=23704623

Family Applications (3)

Application Number Title Priority Date Filing Date
CNB961934565A Expired - Lifetime CN1143688C (zh) 1995-04-26 1996-04-08 透皮促进剂甘油三醋酸酯
CNA2004100392112A Pending CN1507918A (zh) 1995-04-26 1996-04-08 透皮促进剂甘油三醋酸酯
CNB2005100719966A Expired - Lifetime CN100374161C (zh) 1995-04-26 1996-04-08 透皮促进剂甘油三醋酸酯

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CNB961934565A Expired - Lifetime CN1143688C (zh) 1995-04-26 1996-04-08 透皮促进剂甘油三醋酸酯

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB2005100719966A Expired - Lifetime CN100374161C (zh) 1995-04-26 1996-04-08 透皮促进剂甘油三醋酸酯

Country Status (18)

Country Link
US (2) US5601839A (OSRAM)
EP (1) EP0871420B1 (OSRAM)
JP (2) JP3228341B2 (OSRAM)
KR (1) KR100275593B1 (OSRAM)
CN (3) CN1143688C (OSRAM)
AR (1) AR001721A1 (OSRAM)
AT (1) ATE205694T1 (OSRAM)
AU (1) AU696777B2 (OSRAM)
CA (1) CA2217888C (OSRAM)
DE (2) DE69615399T2 (OSRAM)
DK (1) DK0871420T3 (OSRAM)
ES (1) ES2163012T3 (OSRAM)
FR (1) FR05C0008I2 (OSRAM)
NL (1) NL300200I1 (OSRAM)
NZ (1) NZ306249A (OSRAM)
PT (1) PT871420E (OSRAM)
WO (1) WO1996033678A1 (OSRAM)
ZA (1) ZA963229B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103919754A (zh) * 2013-01-15 2014-07-16 江苏康倍得药业有限公司 奥昔布宁药物组合物及其应用

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5633000A (en) * 1994-06-23 1997-05-27 Axxia Technologies Subcutaneous implant
US5785991A (en) * 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
DE69735656T2 (de) * 1996-07-15 2006-08-24 Alza Corp., Mountain View Vorrichtung zur transdermalen Verabreichung von Fluoxetin
US6512010B1 (en) * 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US6479074B2 (en) 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US6290986B1 (en) 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
US6572880B2 (en) 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US5952000A (en) * 1996-10-30 1999-09-14 Theratech, Inc. Fatty acid esters of lactic acid salts as permeation enhancers
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
DE19706824C1 (de) * 1997-02-21 1998-03-26 Lohmann Therapie Syst Lts Transdermales oder topisches Plastersystem mit Polyacrylatmatrix mit verbesserten physikalischen Eigenschaften
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
AU747041B2 (en) 1997-11-10 2002-05-09 Strakan International Limited Penetration enhancing and irritation reducing systems
TW492882B (en) * 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US6210705B1 (en) 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US20020102291A1 (en) * 1997-12-15 2002-08-01 Noven Pharmaceuticals, Inc. Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
EP1459741A1 (en) * 1997-12-15 2004-09-22 Noven Pharmaceuticals, Inc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with menthylphenidate
US6727401B1 (en) * 1998-02-12 2004-04-27 Watson Pharmaceuticals, Inc. Pressure sensitive adhesive matrix patch for the treatment of onychomycosis
DE19812413C1 (de) * 1998-03-20 1999-06-10 Sanol Arznei Schwarz Gmbh Transdermales Therapeutisches System (TTS) Oxybutynin enthaltend
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
US6475514B1 (en) 1998-12-03 2002-11-05 Andrew Blitzer Athletic patch
KR100383252B1 (ko) * 1998-12-17 2003-07-16 주식회사 삼양사 부프레놀핀을함유하는경피투여조성물및이를포함하는패취
WO2000064434A1 (en) * 1999-04-26 2000-11-02 Lead Chemical Co., Ltd. Percutaneous preparations containing oxybutynin
AU6403600A (en) * 1999-06-10 2001-01-02 Sepracor, Inc. Methods and compositions for treating urinary frequency and urgency using optically pure (s)-oxybutynin
US6271219B2 (en) 1999-06-25 2001-08-07 Rajaram Vaidyanathan Topical formulations comprising skin penetration agents and the use thereof
GB9918735D0 (en) * 1999-08-09 1999-10-13 Straken Limited Transdermal patches
US20010049546A1 (en) * 2000-02-08 2001-12-06 Israel Dvoretzky Multi-purpose drug and heat therapy treatment system
US6436428B1 (en) 2000-03-21 2002-08-20 Enhance Pharmaceuticals, Inc. Device and method for treating urinary incontinence in females
US20030124177A1 (en) * 2000-04-26 2003-07-03 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
DE60143477D1 (de) * 2000-04-26 2010-12-30 Watson Pharmaceuticals Inc Verminderung der nebenwirkungen bei der oxybutynin-therapie
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US7029694B2 (en) * 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
CA2418135C (en) * 2000-08-03 2011-09-20 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
EP1372708B1 (en) 2001-02-13 2008-06-18 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE ARMY Vaccine for transcutaneous immunization against travellers' diarrhoea
US6585963B1 (en) * 2001-02-15 2003-07-01 Watson Pharmaceuticals, Inc. Nail compositions and methods of administering same
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
US20030176379A1 (en) * 2001-05-11 2003-09-18 Raoof Araz A. Antisense permeation enhancers
US6913760B2 (en) * 2001-08-06 2005-07-05 New England Medical Hospitals, Inc. Drug delivery composition
AU2002340120A1 (en) * 2001-10-04 2003-04-14 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
US7921999B1 (en) 2001-12-20 2011-04-12 Watson Laboratories, Inc. Peelable pouch for transdermal patch and method for packaging
JP4295467B2 (ja) * 2002-04-12 2009-07-15 日東電工株式会社 貼付剤およびその製造方法
KR100469995B1 (ko) * 2002-05-20 2005-02-05 안국약품 주식회사 천식치료제를 함유한 매트릭스형 패취
JP4323138B2 (ja) * 2002-06-05 2009-09-02 日東電工株式会社 経皮吸収型製剤およびその製造方法
EP1386604A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US20040197397A1 (en) * 2002-08-30 2004-10-07 Watson Pharmaceuticals, Inc. Drug delivery system for treatment of urinary incontinence
DE10251256A1 (de) * 2002-11-04 2004-05-13 Novosis Ag Transdermales Wirkstoffabgabesystem für Oxybutynin
PT1426049E (pt) * 2002-12-02 2005-09-30 Sanol Arznei Schwarz Gmbh Administracao iontoforetica de rotigotina para o tratamento da doenca de parkinson
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
EP1620060B1 (en) * 2003-04-29 2010-03-24 The General Hospital Corporation Methods and devices for the sustained release of multiple drugs
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
PT1670433E (pt) * 2003-10-10 2012-02-08 Ferring Bv Fórmula farmacológica transdérmica para a minimização de resíduos na pele
WO2005077364A1 (ja) * 2004-02-18 2005-08-25 Yamanouchi Pharmaceutical Co., Ltd. ソリフェナシンの経皮投与製剤およびその経皮透過改善方法
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
US8173155B2 (en) * 2004-06-01 2012-05-08 Hisamitsu Pharmaceutical Co., Inc. Adhesive patch
CA2580329C (en) 2004-09-13 2015-01-06 Chrono Therapeutics Inc. Biosynchronous transdermal drug delivery
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US8252320B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
ES2385386T3 (es) 2004-10-21 2012-07-24 Durect Corporation Sistemas de administración transdérmica
US20070053965A1 (en) * 2005-02-25 2007-03-08 Gruenenthal Gmbh Kit comprising a plaster, optionally containing an active substance, and an agent that at least partially reduces skin irritation
US8372040B2 (en) 2005-05-24 2013-02-12 Chrono Therapeutics, Inc. Portable drug delivery device including a detachable and replaceable administration or dosing element
WO2006125642A1 (en) * 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
US20070065494A1 (en) * 2005-08-03 2007-03-22 Watson Laboratories, Inc. Formulations and Methods for Enhancing the Transdermal Penetration of a Drug
US10137135B2 (en) 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
JP5037831B2 (ja) * 2006-02-15 2012-10-03 久光製薬株式会社 凝集力向上及び徐放化の外用貼付剤
EP1998756A2 (en) * 2006-02-27 2008-12-10 Noven Pharmaceuticals, Inc. Compositions and methods for delivery of amino-functional drugs
NZ571460A (en) 2006-04-21 2010-10-29 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
TW200817049A (en) * 2006-06-05 2008-04-16 Verus Pharmaceuticals Inc Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms
WO2007143674A2 (en) * 2006-06-05 2007-12-13 Verus Pharmaceuticals, Inc. Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
DE602007009574D1 (de) * 2006-12-28 2010-11-11 Kaken Pharma Co Ltd Gelzusammensetzung zur behandlung von mykose
NZ552816A (en) * 2007-01-24 2009-05-31 Bomac Research Ltd Formulation for transdermal administration of antihyperthyroid drug comprising a penetration enhancer selected from oleic acid, d-limonene, pyrrolidones, a C2-C8 alcohol, glycol ethers, triacetin and combinations thereof
KR101612901B1 (ko) 2007-03-02 2016-04-15 테이카 세이야쿠 가부시키가이샤 경피흡수 의약조성물, 의약조성물 저장유닛 및 이것을 이용하는 경피흡수제제
US20080226698A1 (en) * 2007-03-16 2008-09-18 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization
US10183001B1 (en) * 2007-05-22 2019-01-22 Pisgah Laboratories, Inc. Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features
EP2182987A4 (en) * 2007-07-30 2011-11-02 Medacure International Inc FORMULATION FOR IMMUNE SYSTEM MODULATOR
US20090098191A1 (en) * 2007-10-16 2009-04-16 Anderson Christopher G Use of bases to stabilize transdermal formulations
KR101539801B1 (ko) * 2007-12-12 2015-07-27 데이고꾸세이약꾸가부시끼가이샤 록소프로펜 함유 수성 첩부제
US20090297591A1 (en) * 2008-05-30 2009-12-03 Orient Pharma Co., Ltd. Compositions And Methods For The Transdermal Delivery Of Pharmaceutical Compounds
US8404255B2 (en) * 2008-07-29 2013-03-26 Matt Gibson System and method for transdermal drug delivery
BRPI0913809B1 (pt) * 2008-10-02 2019-02-05 Mylan Inc método para produzir continuamente um laminado adesivo sensível á pressão multicamada
JP5155128B2 (ja) * 2008-12-11 2013-02-27 日東電工株式会社 メチルフェニデート貼付製剤
US8920392B2 (en) 2009-05-05 2014-12-30 Watson Laboratories, Inc. Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
MX2012004550A (es) * 2009-10-21 2012-05-29 Teikoku Seiyaku Kk Formulacion de absorcion transdermica que contiene donepezil.
AU2010331264B2 (en) 2009-12-15 2014-05-01 Teikoku Seiyaku Co., Ltd. Transdermal preparation containing basic anti-inflammatory agent
WO2011130455A1 (en) 2010-04-13 2011-10-20 Najib Babul Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use
US8748433B2 (en) 2010-04-30 2014-06-10 Merck Sharp & Dohme Corp. β3 adrenergic receptor agonists
FR2972923B1 (fr) * 2011-03-25 2013-08-23 Urgo Lab Composition filmogene contenant un filtre solaire, son utilisation pour le traitement des cicatrices
ES3034911T3 (en) 2011-05-10 2025-08-26 Itochu Chemical Frontier Corp Non-aqueous patch
MX368747B (es) 2011-05-10 2019-10-14 Itochu Chemical Frontier Corp Parche no acuoso de lidocaína y un agente de disolución que comprende un ácido orgánico y un polialcohol que están contenidos en un emplaste para usarse en el tratamiento de dolor muscular a través de la piel.
US11786455B2 (en) 2011-05-10 2023-10-17 Itochu Chemical Frontier Corporation Non-aqueous patch
CN103781478A (zh) * 2011-06-24 2014-05-07 艾森达制药有限公司 用以改善酯类前药吸收率的方法与改良的药学组合物
EP2729148A4 (en) 2011-07-06 2015-04-22 Parkinson S Inst COMPOSITIONS AND METHOD FOR THE TREATMENT OF SYMPTOMS IN PATIENTS WITH MORBUS PARKINSON
HUE039266T2 (hu) 2011-09-27 2018-12-28 Itochu Chemical Frontier Corp Nem-vizes tapasz
WO2013061969A1 (ja) * 2011-10-26 2013-05-02 久光製薬株式会社 オキシブチニン含有経皮吸収製剤
US20130266643A1 (en) * 2012-04-10 2013-10-10 Hpo Life Sciences, Inc. Compositions comprising glyceryl-triacetate (GTA) and uses in human performance optimization and thermogenesis
KR102127625B1 (ko) * 2012-09-03 2020-06-29 다이이찌 산쿄 가부시키가이샤 하이드로모르폰염산염 함유의 경구용 서방성 의약 조성물
JP6374388B2 (ja) 2012-09-21 2018-08-15 インテンシティ セラピューティクス, インク.Intensity Therapeutics, Inc. 癌の治療方法
US9072682B2 (en) 2012-12-31 2015-07-07 Mylan Inc. Transdermal dosage form for low-melting point active agent
US10105487B2 (en) 2013-01-24 2018-10-23 Chrono Therapeutics Inc. Optimized bio-synchronous bioactive agent delivery system
US20140271792A1 (en) * 2013-03-14 2014-09-18 Noven Pharmaceuticals, Inc. Methylphenidate transdermal compositions with rubber-based adhesives
WO2015139847A1 (en) * 2014-03-21 2015-09-24 Chironwells Gmbh 6-(amino acid)-morphinan derivatives in combination with permeation enhancers for use as an orally, rectally, transdermally or nasally administered medicament
CA2973372A1 (en) 2015-01-09 2016-07-14 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system combination
WO2016123406A1 (en) 2015-01-28 2016-08-04 Chrono Therapeutics Inc. Drug delivery methods and systems
CA2977814A1 (en) 2015-03-12 2016-09-15 Chrono Therapeutics Inc. Craving input and support system
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
CN110719778B (zh) 2017-04-24 2024-06-18 才思治疗公司 用于治疗抑郁的组合物和方法
JP2019034905A (ja) * 2017-08-17 2019-03-07 コスメディ製薬株式会社 デヒドロ酢酸含有経皮吸収製剤
WO2019089523A1 (en) * 2017-10-30 2019-05-09 Theracaine Llc Hydrophobic acid addition salts and pharmaceutical formulations thereof
KR101975677B1 (ko) 2017-11-20 2019-05-07 양진석 환편기용 보풀 제거장치
AU2019279884B2 (en) 2018-05-29 2025-01-30 Morningside Venture Investments Limited Drug delivery methods and systems
US12275977B2 (en) 2018-10-26 2025-04-15 Industry-Academic Cooperation Foundation Gyeongsang National University Method for biologically producing acetin compound
JP2022507660A (ja) 2018-11-16 2022-01-18 モーニングサイド ベンチャー インベストメンツ リミテッド 温度によって調節される経皮薬剤送達システム
CN113384558A (zh) * 2021-02-01 2021-09-14 深圳普洛美康材料有限公司 一种递送大麻活性物质的透皮贴剂
JP2022122784A (ja) 2021-02-10 2022-08-23 コスメディ製薬株式会社 酸化防止剤含有経皮吸収製剤
KR20230026232A (ko) 2021-08-17 2023-02-24 신신제약 주식회사 옥시부티닌을 함유하는 경피흡수제제
CN113749968A (zh) * 2021-10-26 2021-12-07 奥易生物科技(杭州)有限公司 一种快速透皮吸收的化妆品及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US466926A (en) * 1892-01-12 Advertising device
US4336262A (en) * 1973-02-23 1982-06-22 Fisons Ltd. Pour-on veterinary anthelmintic
AU576889B2 (en) * 1984-07-24 1988-09-08 Key Pharmaceuticals, Inc. Adhesive transdermal dosage layer
US4895727A (en) * 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
US4666926A (en) * 1986-02-27 1987-05-19 Warner-Lambert Company Transdermal formulations
US4908389A (en) * 1986-08-27 1990-03-13 Warner-Lambert Company Penetration enhancement system
JPH0676327B2 (ja) * 1987-04-14 1994-09-28 株式会社大塚製薬工場 ステロイド軟膏製剤
US4857313A (en) * 1987-05-28 1989-08-15 Warner-Lambert Company Transdermal drug delivery device comprising copolymers of N-morpholinoethyl methacrylate and 2-hydroxylmethacrylate
US4879297A (en) * 1987-06-01 1989-11-07 Warner-Lambert Company Fatty acids and their small chain esters as penetration enhancers in aqueous systems
US4789547A (en) * 1987-06-17 1988-12-06 Warner-Lambert Company Transdermal matrix system
US4814173A (en) * 1987-09-08 1989-03-21 Warner-Lambert Company Silicone elastomer transdermal matrix system
JP2526256B2 (ja) * 1987-11-17 1996-08-21 清水建設株式会社 構造物の振動抑制装置
US5019395A (en) * 1988-03-08 1991-05-28 Warner-Lambert Company Compositions with enhanced penetration
DE3913954A1 (de) * 1989-04-27 1990-10-31 Stief Georg Arzneimittel zur behandlung erektiler dysfunktionen
WO1993009783A1 (en) * 1991-11-15 1993-05-27 Ss Pharmaceutical Co., Ltd. Anti-inflammatory and analgesic plaster
JP3130350B2 (ja) * 1991-11-28 2001-01-31 積水化学工業株式会社 経皮吸収製剤
TW224048B (OSRAM) * 1992-03-30 1994-05-21 Hoechst Roussel Pharma
CA2135925C (en) * 1992-06-11 2001-04-10 Werner E. Heiber Use of glycerin in moderating transdermal drug delivery
JPH08245377A (ja) * 1995-03-15 1996-09-24 Yamanouchi Pharmaceut Co Ltd 経皮吸収用製剤
JPH09309783A (ja) * 1996-05-20 1997-12-02 Chisso Corp 改良された土中崩壊型被覆粒状肥料

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103919754A (zh) * 2013-01-15 2014-07-16 江苏康倍得药业有限公司 奥昔布宁药物组合物及其应用
CN103919754B (zh) * 2013-01-15 2018-11-06 江苏康倍得药业股份有限公司 奥昔布宁药物组合物及其应用

Also Published As

Publication number Publication date
FR05C0008I1 (OSRAM) 2005-04-29
JPH10507199A (ja) 1998-07-14
EP0871420A4 (OSRAM) 1998-11-11
AU696777B2 (en) 1998-09-17
DE69615399D1 (de) 2001-10-25
CA2217888A1 (en) 1996-10-31
ES2163012T3 (es) 2002-01-16
CN100374161C (zh) 2008-03-12
WO1996033678A1 (en) 1996-10-31
FR05C0008I2 (OSRAM) 2007-05-25
DK0871420T3 (da) 2002-01-21
HK1084320A1 (zh) 2006-07-28
ATE205694T1 (de) 2001-10-15
NL300200I1 (nl) 2005-09-01
EP0871420B1 (en) 2001-09-19
JP4511691B2 (ja) 2010-07-28
CN1714867A (zh) 2006-01-04
DE122005000013I1 (de) 2005-06-23
CN1182358A (zh) 1998-05-20
NZ306249A (en) 2000-03-27
CA2217888C (en) 2001-08-28
AR001721A1 (es) 1997-11-26
JP2001039865A (ja) 2001-02-13
US5834010A (en) 1998-11-10
MX9707868A (es) 1997-11-29
KR19990007786A (ko) 1999-01-25
EP0871420A1 (en) 1998-10-21
CN1143688C (zh) 2004-03-31
DE69615399T2 (de) 2003-01-30
PT871420E (pt) 2002-03-28
KR100275593B1 (ko) 2000-12-15
ZA963229B (en) 1997-01-28
US5601839A (en) 1997-02-11
AU5446796A (en) 1996-11-18
JP3228341B2 (ja) 2001-11-12

Similar Documents

Publication Publication Date Title
CN1143688C (zh) 透皮促进剂甘油三醋酸酯
CN1204859C (zh) 用于雌二醇与另一种类固醇物质共同给药的透皮释药基质
US5613958A (en) Transdermal delivery systems for the modulated administration of drugs
EP1163902B1 (en) Transdermal preparation containing hydrophilic or salt-form drug
JP6336476B2 (ja) ホルモン及びその他の薬剤を経皮送達するための組成物及び方法
AU4369493A (en) The use of glycerin in moderating transdermal drug delivery
CN1231592A (zh) 作为渗透促进剂的羟乙酸及其盐的脂肪酸酯
CN1901861A (zh) 透皮递药装置
CN1092287A (zh) 以可变剂量率控制药物经皮释放及其实现方法
CN1578681A (zh) 具有叠层支撑体的贴剂
CN1140265C (zh) 增塑剂及含有该增塑剂的贴剂
CN1489996A (zh) 双氯芬酸钠贴剂及其制备方法
CN1400897A (zh) Lasofoxifene的经皮转运
JPS59104314A (ja) 新規貼付薬
CN1929827A (zh) 包含至少一种脂肪酸的用于二氢吡啶类钙拮抗剂的经皮递送装置
HK1013769A (en) Triacetin as a transdermal penetration enhancer
CN1674914A (zh) 含有雌性激素的贴剂
HK1084320B (en) Triacetin as a transdermal penetration enhancer
CN117797125A (zh) 含有秋水仙碱的贴剂及其制备方法和应用
HK1100525A (en) Transdermal delivery device for dihydropyridine type calcium antagonists containing at least one fatty acid
MXPA97007868A (es) La triacetina como incrementador de penetraciontransdermica
HK1020864B (en) Transdermal drug delivery matrix for coadministering estradiol and another steroid
HK1059225A (en) Composition for the transdermal delivery of fentanyl
HK1025260A (en) Plasticizer and patch containing the plasticizer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication